Business Wire

The Open Group OSDU™ Forum Launches the OSDU Data Platform Mercury Release

24.3.2021 12:00:00 EET | Business Wire | Press release

Share

The Open Group, the vendor-neutral technology consortium, today announced the OSDU Data Platform Mercury Release. Developed by The Open Group OSDU™ Forum, the OSDU Data Platform is an Open Source, standards-based and technology-agnostic data platform for the energy industry that stimulates innovation, industrializes data management, and reduces time to market for new solutions.

The OSDU Data Platform will provide over time access to a vast portfolio of open and proven vendor-developed applications from a broad range of energy sources. By accessing this ecosystem, developers no longer have to develop and maintain the monolithic architecture needed to deliver unique value-add services. Now, with a single set of well-defined and industry-specific APIs, organizations can easily accelerate platform design and develop proprietary applications on top of the OSDU Data Platform.

With an Open Source approach, any company – from established corporations to start-up challenger companies – can contribute new features to the platform, supporting a variety of business workflows. All work is validated by the OSDU Program Management Committee (PMC) to ensure it is aligned with the overall direction of the Forum.

With a single view of industry data, the OSDU Data Platform can be harnessed for innovative business applications. The Mercury Release of the OSDU Data Platform is now available to Operators and Software Developers who want to:

  • Liberate data from traditional silos and make all data discoverable and usable in a single data platform
  • Enable new integrated exploration and development workflows that reduce overall cycle time
  • Take advantage of emerging digital solutions to provide scalability and accelerate decision making

Steve Nunn, President and CEO of The Open Group, commented: “The OSDU Data Platform Mercury Release represents an important achievement by the OSDU Forum in a very short space of time. Established in 2018, the OSDU Forum has accumulated over 185 Member organizations who are collaborating together to accelerate innovation and reduce costs in the energy sector. With a standard data platform, energy companies will be able to drive innovation by integrating digital technologies and utilizing open standards for better decision making. Looking ahead, this will be imperative to meet the world’s increasing energy demands while reducing greenhouse gas emissions.”

Johan Krebbers, GM Emerging Digital Technologies / VP IT Innovation, Shell, commented: “At the heart of most energy companies’ strategies is embracing the transformational technologies taking us forward in today’s digital era. This makes the need for a common architectural design clear, one that underpins how our industry works with its data.”

David Eyton, EVP Innovation & Engineering, bp, commented: “Data is at the heart of bp’s transformation into an integrated energy company. We believe that the future of the energy industry will be data driven and dependent on its ability to manage data in a manner that promotes data sharing with partners, innovation through data science, and rapid decision making throughout the lifecycle of the energy value chains. Being a founding member of the OSDU Forum, bp has had an opportunity to be part of an organization that is fundamentally changing the data landscape for our industry. By integrating energy organizations, cloud services providers, and software vendors, the OSDU Forum is providing an opportunity for collaboration that will be beneficial for all involved. We are very excited about the Mercury Release of the OSDU Data Platform and look forward to expanding this approach into engineering, emissions, and new energy.”

To learn more about how to develop applications the OSDU Data Platform, visit the application developer community page here.

The current OSDU Forum Member List is available here.

-ENDS-

About The Open Group OSDU Forum

The Open Group OSDUTM Forum enables the Energy industry to develop transformational technology to support the world’s changing Energy needs. The OSDU Forum is available to all energy stakeholders including application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found here.

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. For more information, visit www.opengroup.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Jenny Morris
Hotwire
+44 (0)7393465529
UKOpengroup@hotwirepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye